肝细胞癌的临床免疫治疗联合靶向治疗研究进展

Advances in clinical immunotherapy combined with targeted therapy for hepatocellular carcinoma

肝细胞癌(HCC)在我国常见恶性肿瘤排名第四位,对我国人民的生命质量产生严重影响。随着蛋白组学深入研究,学者对肿瘤分子信号通路和微环境了解得不断深入,新型治疗手段靶向治疗、免疫治疗逐渐成为热点。这些治疗手段在临床上能改善晚期HCC患者的预后,但是疗效有限。近年来,研究显示免疫治疗联合靶向治疗可以增强单药治疗的疗效。目前联合治疗策略主要有免疫治疗联合靶向治疗、双免疫联合治疗、靶向局部微创联合治疗,其中免疫治疗联合靶向治疗应用最为广泛。本文比较9种不同的临床免疫治疗联合靶向治疗策略,均能改善患者的生存期,为肝癌患者提供了多种选择,也为以后联合治疗策略的选择药物提供新思路。

Hepatocellular carcinoma(HCC)is the fourth most common malignant tumor in China and has a serious impact on the quality of life of Chinese people.With the in-depth study of proteomics and the deepening understanding of tumor molecular signaling pathways and microenvironment,new therapeutic means targeted therapy and immunotherapy have gradually become a hot spot.These treatments can improve the prognosis of patients with advanced HCC,but the efficacy is limited.In recent years,studies have shown that immunotherapy combined with targeted therapy can enhance the efficacy of monotherapy.At present,the main combined treatment strategies include immunotherapy combined with targeted therapy,dual combined immunotherapy,and targeted local minimally-invasive combined therapy,among which immunotherapy combined with targeted therapy is the most widely used.In this paper,9 different immunotherapy combined with targeted therapy strategies were compared,all of which can improve the survival of patients,provide a variety of options for patients with liver cancer,and also provide a new idea for the selection of drugs for future combination treatment strategies.